KUWAIT CITY, Jan. 27, 2021 /PRNewswire/ -- Dr. Reddy's
Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY)
(NSEIFSC: DRREDDY along with its subsidiaries together referred to
as "Dr. Reddy's") and Global Response Aid FZCO (GRA) today
announced results from an Avigan study on moderate-severe
hospitalized COVID-19 patients in Kuwait.
A sub-group analysis of the low-risk (low NEWS Score at
admission) study cohort (n=181) demonstrated a 3 day earlier
discharge in Avigan group compared to placebo group (8 days vs 11
days; p=0.0063) for time to hospital discharge secondary
endpoint. This endpoint was predefined and showed statistical
significance in a large portion of subjects in this study.
Time to hospital discharge is the best endpoint to determine if
Avigan has a pragmatic effect on patients' duration of
hospitalization, a factor that is relevant to global shortages in
clinical resources and hospital beds induced by the global COVID-19
pandemic.
The findings point favorably towards the hypothesis that an
antiviral drug like Avigan (or similar oral or injectable RNA
polymerases inhibitor) may be effective as part of early treatment
initiation in COVID-19 patients.
As a result of the favorable sub-group data, which are supported
by similar results in Japan-based
clinical trials and real-world studies, Dr.Reddy's and Global
Response Aid have agreed to expedite ongoing Phase 3 pivotal
studies aimed at determining the efficacy of Avigan as an early
treatment for COVID-19 patients with mild-to-moderate symptoms.
Additional studies to evaluate the efficacy of Avigan as part of
early treatment in COVID-19 patients have also been initiated, with
the goal of alleviating symptoms and preventing disease progression
before the infection requires hospitalization or other intensive
interventions.
Other findings from the study of hospitalized patients with
moderate-severe COVID 19 patients showed a one-day reduction in
time to sustained hypoxia resolution for Avigan vs. placebo.
Resolution occurred in seven days vs. eight days. However, the
study did not achieve statistical significance thresholds, and was
terminated. The full final data analysis of the 353 subjects who
were part of the study of hospitalized patients will be available
by end of February 2021.
The study of hospitalized patients was part of an overall
clinical program for Avigan in Kuwait, which covered a spectrum of COVID-19
cases ranging from asymptomatic to severe, in both outpatient and
in-patient settings.
About Global Response Aid (GRA)
Agility (KSE/DFM: AGLTY), one of the world's leading logistics
companies, established Global Response Aid (GRA) to address the
market challenges created by the COVID-19 pandemic and other
threats to public health. GRA delivers innovative, effective
healthcare solutions through a range of pharmaceutical products and
technology platforms. It works closely with governments, regulatory
authorities, hospitals, clinics, healthcare providers, life
sciences companies, NGOs and public institutions to develop
strategies that allow them to tackle public health challenges.
For more information: www.globalresponseaid.com
About Dr. Reddy's
About Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (BSE: 500124,
NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company,
committed to providing affordable and innovative medicines for
healthier lives. Through its three businesses - Pharmaceutical
Services & Active Ingredients, Global Generics and Proprietary
Products – Dr. Reddy's offers a portfolio of products and services
including APIs, custom pharmaceutical services, generics,
biosimilars and differentiated formulations. Our major therapeutic
areas of focus are gastrointestinal, cardiovascular, diabetology,
oncology, pain management and dermatology. Dr. Reddy's operates in
markets across the globe. Our major markets include – USA, India,
Russia & CIS countries, and
Europe.
For more information: www.drreddys.com
View original
content:http://www.prnewswire.com/news-releases/dr-reddys-and-gra-announce-clinically-meaningful-data-from-avigan-pivotal-studies-301216562.html
SOURCE GRA; Agility